Business Wire

MN-VÄRDE-PARTNERS

Share
Värde Partners and Agam Capital Form Life and Retirement Solutions Joint Venture

Värde Partners and Agam Capital announced today an agreement to pursue the acquisition, reinsurance and management of life and retirement businesses globally.

The agreement calls for Värde Partners and Agam Capital to form a joint venture that will combine the investment management expertise of Värde Partners with the proprietary insurance solutions platform developed by Agam. The JV will have the capability to price and manage complex insurance products with embedded market and actuarial risks, on a global basis. It will serve as a turnkey solution for financial modelling and enterprise risk management to provide comprehensive economic solutions to life insurance companies.

In connection with the launch of the JV, Värde Partners is seeking initially to invest $500 million in complex life insurance, annuity, and reinsurance assets that will be supported by the JV. This is part of Värde’s intention to broaden its investing in targeted sub-sectors of the financial services industry, marking the expansion of its private equity strategy into insurance.

Elena Lieskovska, Partner and Head of European Financial Services at Värde Partners, said:
“Given the current landscape of historically low interest rates and fundamental regulatory and accounting changes, we believe the opportunity across the $23 trillion life insurance industry is huge. Life insurance companies are increasingly seeking risk mitigation solutions for legacy blocks of liabilities with multi-dimensional risks. This is particularly true for complex annuity products, such as those with high guarantees or exposure to certain market risks, which typically attract a higher capital charge. We are excited to expand Värde’s financial services footprint into insurance, and partner with Agam to provide alternative solutions to the industry.”

Agam’s Co-Founders, Avi Katz and Chak Raghunathan said:
“The need for multi-dimensional solutions to the complex changes facing the life insurance industry has never been greater. Against this backdrop, we believe the combination of Värde Partner’s core strengths in complex transactions together with Agam’s differentiated pALM platform will create a world-class insurance solutions provider. In particular, the Agam platform is designed to price, analyze and manage complex insurance products with embedded capital market risks and offers creative structures and solutions on a global basis.”

Agam’s highly scalable, proprietary technology platform applies machine learning, predictive data analytics and cloud computing to evaluate and assess complex insurance liabilities. Its innovative approach incorporates advanced analytical techniques, including integrating transaction modelling with actuarial cash flows.

About Värde Partners
Värde Partners is a $14 billion global alternative investment firm that employs a value-based approach to investing across a broad array of geographies, segments and asset types, including corporate and traded credit, real estate, mortgages, financial services, real assets and infrastructure. The firm sponsors and manages a family of private investment funds with a global investor base that includes foundations and endowments, pension plans, insurance companies, other institutional investors and private clients. Now in its third decade, Värde employs more than 300 people globally with regional headquarters in Minneapolis, London and Singapore.

About Agam Capital
Agam is a New Jersey-based insurance solutions provider, founded by Abraham Katz and Chak Raghunathan, senior executives from Apollo Global Management and Aflac Inc. While traditional insurance solutions have been aimed at enhancing asset yield to support a liability structure, Agam has focused its efforts on building technology for risk management with integrated analytics. Agam’s expertise is to develop solutions for complex cash flow streams through greater hedging optimization and meaningfully lower operating costs.

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Scoring Big With Fans: Balchem Spotlights the Power of Vitamin K2 at FC Bayern Women’s Season Opener18.9.2025 14:33:00 CEST | Press release

Balchem, a leading global manufacturer of specialty ingredients for human nutrition and health – and official partner of FC Bayern (FCB) Women’s football team - has launched its first ever direct-to-consumer initiative, showcasing the power of vitamin K2 to FCB fans. The company promoted its K2VITAL™ brand with an exhibition stand at the Allianz Arena in Munich, during the opening game of the Bundesliga (German football league) on 6 September. This initiative is part of Balchem’s latest marketing strategy, which aims to raise consumer awareness of the health benefits vitamin K2 has to offer, bridging the gap between B2B and B2C markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250918950889/en/ Balchem Spotlights The Power of Vitamin K2 at FC Bayern Women’s Season Opener Co-Branded K2 Health Vitamins Hit the Pitch The opening event of the season provided a unique platform for Balchem to promote K2VITAL™, a patented, typ

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy18.9.2025 14:30:00 CEST | Press release

- CASGEVY is the first, and only, gene editing therapy approved for the treatment of transfusion-dependent beta thalassemia (TDT) and sickle cell disease (SCD) in Europe -- Italy has the largest population of people living with TDT in Europe- Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with the Italian Medicines Agency (AIFA) for eligible transfusion-dependent beta thalassemia (TDT) and severe sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® (exagamglogene autotemcel). “Today is a turning point for eligible people in Italy living with transfusion-dependent beta thalassemia and sickle cell disease, two life-shortening diseases with limited treatment options,” said Ludovic Fenaux, Senior Vice President, Vertex International. “Italy has the largest TDT population in Europe, which underscores the importance of this agreement. We appreciate the collaboration with AIFA to recognize the value a one-time transformati

European DataWarehouse Appoints Nigel Batley as Executive Director of Its UK Subsidiary18.9.2025 12:41:00 CEST | Press release

European DataWarehouse Ltd. (EDW Ltd.) the UK subsidiary of European DataWarehouse GmbH, today announced the appointment of Nigel Batley as Executive Director. Mr. Batley succeeds Markus Schaber, who will retire from the role after serving as Executive Director since 2020. With nearly 40 years of experience in the financial services industry, Mr. Batley brings extensive expertise in asset-backed finance. He spent more than 30 years at HSBC, where he held senior positions including Global Head of Structured Finance, before taking on advisory and leadership roles in the securitisation market. Markus Schaber, outgoing Executive Director of EDW Ltd., will remain with the company as Senior Advisor. He commented: “It has been a privilege to lead European DataWarehouse in the UK and contribute to the development of greater transparency in European securitisation markets. I am confident that Nigel’s deep industry knowledge and leadership will strengthen EDW Ltd.’s mission and ensure we continu

Zycus Recognized as A Customers’ Choice in 2025 Gartner® Peer Insights™ “Voice of the Customer” for Source-to-Pay Suites18.9.2025 11:20:00 CEST | Press release

Zycus, a global leader in procurement and source-to-pay transformation, today announced it has been recognized as A Customers’ Choice in 2025 Gartner Peer Insights™ “Voice of the Customer”: Source-to-Pay Suites report. The Gartner Peer Insights report aggregates ratings and reviews from verified end users over an 18-month ending June 30, 2025. To qualify, vendors must have at least 20 eligible reviews and meet thresholds for capabilities and support. In the 2025 report, only eight vendors qualified, with Zycus placed in the Customers’ Choice quadrant — highlighting vendors rated above the market average for both Overall Experience and User Interest & Adoption. Recognition Backed by Customer Experience According to the report, Zycus achieved: 4.6 out of 5 Overall Rating, based on 67 peer reviews as of June 30, 2025. 95% willingness to recommend score – reflecting customer trust and satisfaction. Ratings across Product Capabilities, Sales Experience, Deployment, and Support, each above 4

Neumirna Therapeutics Appoints Ellen K. Donnelly as Chief Executive Officer18.9.2025 11:00:00 CEST | Press release

Neumirna Therapeutics, a biotechnology company developing RNA-based therapies for neurological diseases, today announced the appointment of Ellen K. Donnelly, Ph.D. as Chief Executive Officer. Ellen brings more than 20 years of leadership in neuroscience and rare diseases, spanning both global pharmaceutical companies and innovative biotech firms. She joins Neumirna from her role as CEO of Abliva AB, recently acquired by Pharming Group, and has previously led Modus Therapeutics and Souvien Therapeutics. Earlier in her career, Ellen spent nearly a decade at Pfizer Inc., where she held leadership roles in neuroscience research, clinical operations, portfolio management, and strategy. She holds a Ph.D. in Pharmacology & Neuroscience from Yale University. "Ellen combines scientific expertise with proven leadership in both biotech and pharma," said Luis Pareras, Chairman of the Board at Neumirna. "The Board is confident that under her guidance, Neumirna will continue to translate our innova

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye